1. Home
  2. MODD vs RVPH Comparison

MODD vs RVPH Comparison

Compare MODD & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Modular Medical Inc.

MODD

Modular Medical Inc.

HOLD

Current Price

$0.47

Market Cap

33.3M

Sector

Health Care

ML Signal

HOLD

Logo Reviva Pharmaceuticals Holdings Inc.

RVPH

Reviva Pharmaceuticals Holdings Inc.

HOLD

Current Price

$0.26

Market Cap

35.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MODD
RVPH
Founded
1998
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.3M
35.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MODD
RVPH
Price
$0.47
$0.26
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$3.14
AVG Volume (30 Days)
171.3K
2.6M
Earning Date
02-13-2026
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$0.25
52 Week High
$1.29
$1.90

Technical Indicators

Market Signals
Indicator
MODD
RVPH
Relative Strength Index (RSI) 52.53 33.44
Support Level $0.42 $0.25
Resistance Level $0.49 $0.31
Average True Range (ATR) 0.04 0.02
MACD -0.00 0.00
Stochastic Oscillator 48.41 15.09

Price Performance

Historical Comparison
MODD
RVPH

About MODD Modular Medical Inc.

Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

Share on Social Networks: